Method for treating SARS-COV-2 infectious disease
AssigneeResearch & Business Foundation Sungkyunkwan University
InventorWonhwa Lee
Life of this patent
Estimating the term…
Abstract
Disclosed are a composition for diagnosis of SARS-CoV-2 infectious disease, a diagnostic kit, a method for providing information for diagnosis, a method for screening a therapeutic agent, and a composition for prevention or treatment, wherein it is expected that the diagnosis or prognostic prediction of the severity of SARS-CoV-2 infectious disease can be attained and the control of expression and activity of TOX, which is a marker, can be advantageously used in the development of a therapeutic agent for SARS-CoV-2 infectious disease.
Claims3
A method for treating SARS-CoV-2 infectious disease accompanied by sepsis or acute respiratory distress syndrome (ARDS) in a subject in need thereof, the method comprising
- administering to the subject a therapeutically effective amount of a TOX-directed inhibitory agent selected from the group consisting of:
- (i) an antibody or antigen-binding fragment that specifically binds thymocyte selection-associated high mobility group box (TOX) protein comprising SEQ ID NO:
- 1;
- and (ii) an siRNA or shRNA that specifically hybridizes to a polynucleotide comprising SEQ ID NO:
- 2 encoding human TOX.
A method for treating a patient infected with SARS-CoV-2 and accompanied by sepsis or acute respiratory distress syndrome (ARDS), the method comprising:
- obtaining a biological sample from the patient;
- measuring TOX protein level or TOX mRNA expression level in the biological sample;
- comparing the measured TOX protein level or TOX mRNA expression level with that of a normal control group;
- determining that the measured TOX protein level or TOX mRNA expression level is at least two-fold higher than that of the normal control group;
- and
- administering to the patient a therapeutically effective amount of a TOX-directed inhibitory agent selected from the group consisting of:
- (i) an antibody or antigen-binding fragment that specifically binds thymocyte selection-associated high mobility group box (TOX) protein comprising SEQ ID NO:
- 1;
- and (ii) an siRNA or shRNA that specifically hybridizes to a polynucleotide comprising SEQ ID NO:
- 2 encoding human TOX.
Dependencies are inferred from the claim text.